Plain-English translation of NCT05305911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether SGLT2 inhibitors—a class of medication originally developed to help manage blood sugar—can help your heart recover better after a severe heart attack called a STEMI. The study will compare this medication against a placebo (a dummy pill) in patients who had successful emergency treatment but still show signs of heart stress. Researchers want to see if the medication can improve how well your heart pumps and prevent it from becoming enlarged over time.
After a severe heart attack, even with emergency treatment, some areas of the heart don't get enough blood flow, which can lead to permanent damage and a weakened heart. This trial exists to see whether this medication can reduce that damage and help your heart function better, potentially preventing future heart problems.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either the medication or a placebo, both taken once daily for 6 months alongside your regular heart attack medications. You'll have a heart MRI scan during your initial hospitalization, follow-up phone calls at 1 and 3 months to check how you're doing, and a final clinic visit with another heart MRI scan at 6 months. This is a single-center study, meaning all visits occur at one hospital location.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
United States